Innovation Pharma Completes Interim Safety Data Review—DMC Approves Increased Dosing Frequency in Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
April 05, 2021 07:30 ET
|
Innovation Pharmaceuticals Inc.
Study drug dosing regimen to increase to 5 days (from 3 days) based on DMC recommendationEnrollment has reached 25 percent in the Company’s ~120-patient Phase 2 COVID-19 clinical trial WAKEFIELD,...
Innovation Pharma’s COVID-19 Drug Candidate Brilacidin Ranked in Top Three Percent of Compounds Predicted to Be Most Effective Against SARS-CoV-2
March 10, 2021 07:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report today that a Machine...
Recruitment and Enrollment Underway at Eight Sites for Innovation Pharma’s Phase 2 Clinical Trial of Brilacidin for COVID-19
March 05, 2021 11:31 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports that eight sites are now...
Innovation Pharmaceuticals Announces Publication of Peer-Reviewed Scientific Article in the Journal Viruses on the Anti-SARS-CoV-2 Properties of Brilacidin
March 02, 2021 09:00 ET
|
Innovation Pharmaceuticals Inc.
Emerging mutations to the coronavirus are unlikely to affect Brilacidin’s ability to inhibit the virusBrilacidin currently is being evaluated in a Phase 2 clinical trial in hospitalized COVID-19...
Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
February 26, 2021 09:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides additional study details for...
Innovation Pharmaceuticals’ Phase 2 Clinical Trial of Brilacidin for Treating COVID-19 Scheduled to Begin Next Week
January 29, 2021 09:15 ET
|
Innovation Pharmaceuticals Inc.
Brilacidin treatment unlikely to be impacted by coronavirus variants, such as those originating in the U.K., South Africa and Brazil, and spreading worldwide, due to its ability to attack the virus...
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation
January 14, 2021 07:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the U.S. Food and...
FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals’ Brilacidin for Treating COVID-19
December 21, 2020 07:00 ET
|
Innovation Pharmaceuticals Inc.
Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United...
Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic
November 30, 2020 09:00 ET
|
Innovation Pharmaceuticals Inc.
Company advancing Brilacidin as a next-generation broad-spectrum antiviral for the treatment of common colds and deadly coronavirus infections WAKEFIELD, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) --...
Innovation Pharmaceuticals Announces Overseas Regulatory Filing Submitted For COVID-19 Clinical Study
November 16, 2020 09:00 ET
|
Innovation Pharmaceuticals Inc.
New in vitro data also demonstrates Brilacidin’s anti-SARS-CoV-2 potency is unlikely to be impacted by mutations in different strains of the virus WAKEFIELD, Mass., Nov. 16, 2020 (GLOBE...